PURPOSE: The purpose of this study was to determine whether specific HOXA epigenetic signatures could differentiate glioma with distinct biological, pathological, and clinical characteristics. METHODS: We evaluated HOXA3, 7, 9, and 10 methylation in 63 glioma samples by MassARRAY and pyrosequencing. RESULTS: We demonstrated the direct statistical correlation between the level of methylation of all HOXA genes examined and WHO grading. Moreover, in glioblastoma patients, higher level of HOXA9 and HOXA10 methylation significantly correlated with increased survival probability (HOXA9-HR: 0.36, P = 0.007; HOXA10-HR: 0.46, P = 0.045; combined HOXA9 and 10-HR 0.28, P = 0.004). CONCLUSIONS: This study identifies HOXA3, 7, 9, and 10 as methylation targets mainly in high-grade glioma and hypermethylation of the HOXA9 and 10 as prognostic factor in glioblastoma patients. Our data indicate that these epigenetic changes may be biomarkers of clinically different subgroups of glioma patients that could eventually benefit from personalized therapeutic strategies.
PURPOSE: The purpose of this study was to determine whether specific HOXA epigenetic signatures could differentiate glioma with distinct biological, pathological, and clinical characteristics. METHODS: We evaluated HOXA3, 7, 9, and 10 methylation in 63 glioma samples by MassARRAY and pyrosequencing. RESULTS: We demonstrated the direct statistical correlation between the level of methylation of all HOXA genes examined and WHO grading. Moreover, in glioblastomapatients, higher level of HOXA9 and HOXA10 methylation significantly correlated with increased survival probability (HOXA9-HR: 0.36, P = 0.007; HOXA10-HR: 0.46, P = 0.045; combined HOXA9 and 10-HR 0.28, P = 0.004). CONCLUSIONS: This study identifies HOXA3, 7, 9, and 10 as methylation targets mainly in high-grade glioma and hypermethylation of the HOXA9 and 10 as prognostic factor in glioblastomapatients. Our data indicate that these epigenetic changes may be biomarkers of clinically different subgroups of gliomapatients that could eventually benefit from personalized therapeutic strategies.
Authors: Michael Weller; Roger Stupp; Guido Reifenberger; Alba A Brandes; Martin J van den Bent; Wolfgang Wick; Monika E Hegi Journal: Nat Rev Neurol Date: 2009-12-08 Impact factor: 42.937
Authors: Mathias Ehrich; Matthew R Nelson; Patrick Stanssens; Marc Zabeau; Triantafillos Liloglou; George Xinarianos; Charles R Cantor; John K Field; Dirk van den Boom Journal: Proc Natl Acad Sci U S A Date: 2005-10-21 Impact factor: 11.205
Authors: Martin Widschwendter; Sophia Apostolidou; Allison A Jones; Evangelia O Fourkala; Rupali Arora; Celeste Leigh Pearce; Melissa A Frasco; Ayse Ayhan; Michal Zikan; David Cibula; Cem A Iyibozkurt; Ekrem Yavuz; Cornelia Hauser-Kronberger; Louis Dubeau; Usha Menon; Ian J Jacobs Journal: Int J Cancer Date: 2009-11-01 Impact factor: 7.396
Authors: Barbara Banelli; Stefano Bonassi; Ida Casciano; Katia Mazzocco; Angela Di Vinci; Paola Scaruffi; Claudio Brigati; Giorgio Allemanni; Luana Borzì; Gian Paolo Tonini; Massimo Romani Journal: Int J Cancer Date: 2010-02-01 Impact factor: 7.396
Authors: Tibor Rauch; Zunde Wang; Xinmin Zhang; Xueyan Zhong; Xiwei Wu; Sean K Lau; Kemp H Kernstine; Arthur D Riggs; Gerd P Pfeifer Journal: Proc Natl Acad Sci U S A Date: 2007-03-16 Impact factor: 11.205
Authors: Monika E Hegi; Lili Liu; James G Herman; Roger Stupp; Wolfgang Wick; Michael Weller; Minesh P Mehta; Mark R Gilbert Journal: J Clin Oncol Date: 2008-09-01 Impact factor: 44.544
Authors: Manoela Carrera; Carolina C Bitu; Carine Ervolino de Oliveira; Nilva K Cervigne; Edgard Graner; Aki Manninen; Tuula Salo; Ricardo D Coletta Journal: Int J Clin Exp Pathol Date: 2015-04-01
Authors: Fred H Hochberg; Nadia A Atai; David Gonda; Michael S Hughes; Brolin Mawejje; Leonora Balaj; Robert S Carter Journal: Expert Rev Mol Diagn Date: 2014-05 Impact factor: 5.225
Authors: Juliana Schussel; Xian Chong Zhou; Zhe Zhang; Kavita Pattani; Francisco Bermudez; Germain Jean-Charles; Thomas McCaffrey; Tapan Padhya; Joan Phelan; Silvia Spivakovsky; Mariana Brait; Ryan Li; Helen Yoo Bowne; Judith D Goldberg; Linda Rolnitzky; Miriam Robbins; A Ross Kerr; David Sirois; Joseph A Califano Journal: Clin Cancer Res Date: 2013-05-01 Impact factor: 12.531